GoAI
Get started
Genelux Corporation logo

Genelux Corporation

GNLX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$2.71

−$0.02 · -0.73%

Aug 21, 3:55 PM ET

GNLX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

12

Overpriced

Momentum

39

Weakening

Sentiment

53

Mixed

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Thomas D. Zindrick
Listed since
Jan 26, 2023
Employees
26

Market position

Volume
223.75K
1.08× average
Average volume
207.03K
Average daily volume
Market cap
121.97M USD
Beta
0.59
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.06×
P/B (TTM)
7.59×
P/S (TTM)
15,245.74×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-1762.50%
Operating margin
-445200.00%
Net margin
-422412.50%

Financial health

Debt / equity
0.15×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends41618%-124489%-290595%-456702%Gross margin, FY2022: 91.25%Gross margin, FY2023: -498.82%Gross margin, FY2024: -11187.50%Gross margin, FY2025: -7075.00%Operating margin, FY2022: -27.22%Operating margin, FY2023: -14214.71%Operating margin, FY2024: -396200.00%Operating margin, FY2025: -415175.00%Net margin, FY2022: -47.05%Net margin, FY2023: -16645.29%Net margin, FY2024: -373362.50%Net margin, FY2025: -401812.50%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 91.25%. Gross margin FY2023 -498.82%. Gross margin FY2024 -11187.50%. Gross margin FY2025 -7075.00%. Operating margin FY2022 -27.22%. Operating margin FY2023 -14214.71%. Operating margin FY2024 -396200.00%. Operating margin FY2025 -415175.00%. Net margin FY2022 -47.05%. Net margin FY2023 -16645.29%. Net margin FY2024 -373362.50%. Net margin FY2025 -401812.50%.

Income trends

Revenue

8K USD0.00%

Operating income

−33.21M USD-4.79%

Net income

−32.15M USD-7.62%
Income trends across reported periods15.5M USD−2.22M USD−19.93M USD−37.64M USDRevenue, FY2022: 11.07M USDRevenue, FY2023: 170K USDRevenue, FY2024: 8K USDRevenue, FY2025: 8K USDOperating income, FY2021: −14.61M USDOperating income, FY2022: −3.01M USDOperating income, FY2023: −24.17M USDOperating income, FY2024: −31.7M USDOperating income, FY2025: −33.21M USDNet income, FY2021: −17.8M USDNet income, FY2022: −5.21M USDNet income, FY2023: −28.3M USDNet income, FY2024: −29.87M USDNet income, FY2025: −32.15M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 11.07M USD. Revenue FY2023 170K USD. Revenue FY2024 8K USD. Revenue FY2025 8K USD. Operating income FY2021 −14.61M USD. Operating income FY2022 −3.01M USD. Operating income FY2023 −24.17M USD. Operating income FY2024 −31.7M USD. Operating income FY2025 −33.21M USD. Net income FY2021 −17.8M USD. Net income FY2022 −5.21M USD. Net income FY2023 −28.3M USD. Net income FY2024 −29.87M USD. Net income FY2025 −32.15M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8K USD8K USD170K USD11.07M USD—
Cost of goods sold574K USD903K USD1.02M USD968K USD895K USD
Gross profit−566K USD−895K USD−848K USD10.1M USD−895K USD
Research and development19.85M USD19M USD12.77M USD9.08M USD6.32M USD
Selling, general, and administrative13.37M USD12.71M USD11.57M USD5M USD8.29M USD
Operating expenses32.65M USD30.8M USD23.32M USD13.11M USD13.72M USD
Interest income1.07M USD1.46M USD244K USD——
Interest expense——3.97M USD1.41M USD1.82M USD
Depreciation and amortization574K USD903K USD1.02M USD968K USD895K USD
Operating income−33.21M USD−31.7M USD−24.17M USD−3.01M USD−14.61M USD
Net income−32.15M USD−29.87M USD−28.3M USD−5.21M USD−17.8M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$17.33

537.13% upside
Past 12 months12-month forecastHigh $20.00Average $17.33Low $16.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy267%
Hold133%
Sell00%
Strong sell00%

GNLX news

globenewswire.com

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates…

Read source
defenseworld.net

Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday

Genelux (NASDAQ: GNLX - Get Free Report) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.…

Read source
globenewswire.com

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -

Read source

GNLX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GNLX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.51M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.37M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
383.22K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research GNLX

research.disclaimer